Janet Jill Hopkins Sells 2,534 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 2,534 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total value of $19,638.50. Following the sale, the insider now owns 269,794 shares in the company, valued at $2,090,903.50. The trade was a 0.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Aura Biosciences Trading Down 3.8 %

Shares of AURA traded down $0.30 during mid-day trading on Tuesday, reaching $7.65. The company’s stock had a trading volume of 213,354 shares, compared to its average volume of 139,966. Aura Biosciences, Inc. has a 1-year low of $6.63 and a 1-year high of $12.38. The business has a 50-day simple moving average of $8.07 and a two-hundred day simple moving average of $8.76. The stock has a market cap of $382.12 million, a P/E ratio of -4.42 and a beta of 0.29.

Institutional Investors Weigh In On Aura Biosciences

Hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC bought a new position in Aura Biosciences in the 4th quarter valued at about $127,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Aura Biosciences by 27.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company’s stock worth $1,122,000 after buying an additional 29,618 shares in the last quarter. Ensign Peak Advisors Inc boosted its position in shares of Aura Biosciences by 43.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after acquiring an additional 118,000 shares during the period. Deutsche Bank AG grew its stake in shares of Aura Biosciences by 56.7% in the fourth quarter. Deutsche Bank AG now owns 44,085 shares of the company’s stock valued at $362,000 after acquiring an additional 15,951 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Aura Biosciences by 20.5% during the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock worth $422,000 after acquiring an additional 8,709 shares during the period. Institutional investors and hedge funds own 96.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences currently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.